Eyenovia | 8-K: Eyenovia Reports First Quarter 2024 Financial Results and Provides Updates on its Myopia Phase III Program and its Two FDA Approved Commercial Products, Mydcombi and Clobetasol
Eyenovia | 8-K: Eyenovia Reports First Quarter 2024 Financial Results and Provides Updates on its Myopia Phase III Program and its Two FDA Approved Commercial Products, Mydcombi and Clobetasol
Eyenovia | 8-K：Eyenovia公佈了2024年第一季度財務業績，並提供了其近視三期計劃及其兩款經美國食品藥品管理局批准的商用產品Mydcombi和Clobetasol的最新情況
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。